In lung cancer cases, based on a multicenter phase-I clinical trial, the response of anti-PD-1 antibodies was correlated with higher PD-L1 tumor expression in advanced non-small-cell lung cancer patients [17]. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.